Form 4: Regeneron Director Exercises Options, Sells Shares

A Regeneron Pharmaceuticals director exercised stock options and subsequently sold shares under a pre-arranged 10b5-1 plan.

Summary

• Huda Y. Zoghbi, a Director at Regeneron Pharmaceuticals, Inc. (REGN), engaged in transactions involving the company's common stock.
• On February 19, 2026, Zoghbi exercised 1,638 Non-Qualified Stock Options at an exercise price of $376.69 per share.
• Concurrently, Zoghbi sold 1,638 shares of common stock in multiple transactions at volume-weighted average prices ranging from $774.68 to $790.00 per share.
• These transactions were conducted pursuant to a Rule 10b5-1(c) trading plan adopted on November 20, 2025.
• Following these transactions, Zoghbi's direct beneficial ownership of Regeneron common stock decreased to 1,703 shares.
• Zoghbi now beneficially owns 800 derivative securities (Non-Qualified Stock Options).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, typical for an insider exercising vested options and selling shares under a pre-arranged 10b5-1 plan, which minimizes any negative signaling often associated with discretionary insider sales.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 plan, indicating a planned liquidity event rather than a reaction to immediate market conditions.
• The exercise of options at $376.69 and subsequent sale at prices up to $790.00 demonstrates a significant profit for the insider on the exercised options.

Negatives

• A director's net reduction in direct share ownership, even if pre-planned, can sometimes be perceived as a lack of confidence, though this is often for diversification or tax planning.

Future Outlook

No future outlook or guidance is provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common for executives and directors seeking to manage personal finances, diversify holdings, or exercise vested options while mitigating concerns about trading on material non-public information. This type of transaction is standard practice in the pharmaceutical and biotechnology sectors for long-tenured directors.

Comparison to Industry Standards

• Insider transactions under 10b5-1 plans are a standard practice across industries, including pharmaceuticals, for managing personal liquidity and tax obligations.
• The exercise of options and subsequent sale at a significantly higher market price is typical for vested equity compensation, reflecting the growth in the company's stock value since the option grant.
• Comparable companies like Pfizer, Merck, or Johnson & Johnson frequently report similar Form 4 filings from their directors and executives.

Stakeholder Impact

• Shareholders: The net reduction in a director's direct shareholding might be viewed with slight caution, but the pre-planned nature mitigates concerns. The overall impact is likely minimal given the routine nature of the transaction.

Key Dates

Recommendation

The filing details a routine insider transaction involving the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 plan. This type of transaction is common for directors managing personal finances and does not typically signal a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this disclosure. Investors should maintain their current position and consider broader company performance and market trends.

Keywords

Regeneron Pharmaceuticals, REGN, Insider Trading, Form 4, Stock Options, Share Sale, Director Transaction, 10b5-1 Plan, Biotechnology, Pharmaceuticals